SAFETY // FEW HUMAN STUDIES
What remains unknown about BPC-157 TB-500 side effects?
Small, brief human studies couldn't settle safety over years of use. Lab tests linked Thymosin Beta-4 to tumor cells moving and new blood vessels growing. Neither finding tested the mixture in people. Your cancer risk from the pair hasn't been proved or ruled out.
What can brief human studies tell you about harm?
Early human tests were too small to settle risks over years [8][9]. A controlled human comparison hasn't measured BPC-157 TB-500 side effects from the mixture. TB-500 itself also lacks a careful human safety comparison. Better animal healing doesn't tell you what unwanted effects a person might have.
The 2025 review examined a 36-study collection concerning BPC-157 without finding careful human safety results [8]. Three early human studies were small and couldn't settle whether unwanted effects make the substance unsafe. Human findings often credited to TB-500 came from complete Thymosin Beta-4 [7]. For you, the short part's unwanted effects remain untested by those studies.
The 2026 Sports Medicine review warned that human safety research was too limited [9]. The review included BPC-157 and TB-500 among unapproved substances discussed for muscle and joint injuries. Use often lacked the checks required for approved medicines, leaving serious harm possible. Adding another ingredient doesn't answer either substance's unanswered safety questions, because you still need a comparison of what happens to people receiving the pair and people who don't receive both.
Have trials settled BPC-157 and TB-500 unwanted effects?
A trial hasn't settled the mixture's side effects or safety after long use [8][9]. Thymosin Beta-4 lab findings raised questions about tumors and their blood supply [4][9]. BPC-157 had three small human studies; complete Thymosin Beta-4 had Phase 1 tests, early checks for immediate unwanted effects. Brief checks can't tell you that years of receiving both would be safe.
How could Thymosin Beta-4 changes help tumors?
These were tumor and cell tests, leaving your risk from the mixture unanswered [5]. Thymosin Beta-4 was linked to spreading tumors and an added blood supply around them. Cells must reach injured skin, which also needs its blood supply restored. Tumors can use moving cells and added blood supply too, raising concern about repair changes [5][4].
No study tested whether people given the mixture developed cancer [5]. Several kinds of cancer cells produced more Thymosin Beta-4 than usual. Those findings concerned tumors and cells rather than a mixture treatment in people. Encouraging tissue repair could also encourage unwanted growth, but that possibility remains unsettled [4].
Does the lab concern mean TB-500 caused cancer in people?
The lab work connected Thymosin Beta-4 with spreading tumors and growing blood vessels [5]. Cells moving across a wound can help repair, while cancer cells moving can help spread cancer. Researchers haven't shown that a TB-500 mixture causes human cancer [5][8]. You have an unanswered risk, rather than proof of either safety or harm.
What didn't improve when mouse muscles grew new fibers?
The tests were in animals, and more repair didn't always mean more strength [4]. For you, new tissue would need to help your muscles do their work. A sign of tissue growing doesn't establish that walking or movement improves. Results that didn't help strength matter as much as hopeful wound findings.
Mice with an inherited muscle illness received Thymosin Beta-4 for six months [6]. Each shot delivered 150 micrograms, each microgram equaling one millionth of a gram. Researchers injected the belly space surrounding the organs twice each week. New fibers formed in mouse muscles, but strength and heart function didn't improve, and scarring stayed high.
In rats with strokes, Thymosin Beta-4 also failed to help at a larger amount [4]. That amount was 18 milligrams for each kilogram the rat weighed, calculated according to body size. Giving more therefore didn't assure the rats a better result. The study doesn't set an amount or treatment plan for your care.
Can those animal tests settle safety after repeated use?
Long-term human safety comparisons are missing for BPC-157, TB-500, and the pair [8][9]. Mice given Thymosin Beta-4 had new fibers without improved strength, heart function, or scarring [6]. Reviews called for further study because there were too few human findings [8][10]. Those limits prevent an assurance that repeated use would be safe for you.
Why can't another substance's safety results settle the short part's safety?
Reviewers warned that human studies leave major safety questions unanswered [8][9][10]. A result about BPC-157 alone doesn't establish how another substance affects people. For your choice, the important question is what researchers actually gave the people studied. For your safety, that answer matters more than the bottle name, because the short part and the complete substance haven't had the same tests to show how people respond.
What concerns did the reviews share?
The 2025 reviewers found BPC-157 studies too limited to support firm treatment claims [8]. The 2026 Sports Medicine review cautioned that serious harm remained possible with too little careful human research [9]. BPC-157 and TB-500 were among the unapproved substances discussed for muscle and joint injuries. Another 2025 review noted few human findings and bottles sold without the checks used for approved medicines [10].
TB-500 is the short part; complete Thymosin Beta-4 is a different substance. Their weights are about 889 daltons and 4963 daltons respectively, using a lab unit of weight. Those weights don't tell you side effects: most healing and early safety findings used the complete substance [4][7]. TB-500 still lacks the careful human safety tests needed to answer your question.
Bottles marked BPC-157 and TB-500 may hold wrong substances, unexpected material, or amounts differing from the label [3]. You may therefore be unable to tell exactly what someone received. Wolverine legal status and 503A pharmacy rules explains the unsettled permission to prepare medicine. The papers listed here show which substance each test used.
Clinical boundaries
Safety evidence and prescription care are separate questions
The published safety record for Wolverine (research blend) is thin: small BPC-157 pilots, full-length thymosin beta-4 work, and nothing on the assembled blend. Prescription care is the other path, and at Promise Peptides (mypromise.com) it starts with a licensed prescriber evaluating the patient before deciding whether it fits.